Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated, recurrent epithelial ovarian cancer

被引：0
|
作者：
Hurt, J. [1 ]
Backes, F. [1 ]
Rheaume, S. [1 ]
Richardson, D. [1 ]
Fowler, J. [1 ]
Copeland, L. [1 ]
Cohn, D. [1 ]
Eisenhauer, E. [1 ]
Salani, R. [1 ]
O'Malley, D. [1 ]
机构：
[1] Ohio State Univ, Columbus, OH 43210 USA
来源：
GYNECOLOGIC ONCOLOGY | 2010年 / 116卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
120
引用
收藏
页码：S47 / S47
页数：1
相关论文
共 50 条
  • [1] Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer
    O'Malley, David M.
    Richardson, Debra L.
    Rheaume, Patrick S.
    Salani, Ritu
    Eisenhauer, Eric L.
    McCann, Georgia A.
    Fowler, Jeffrey M.
    Copeland, Larry J.
    Cohn, David E.
    Backes, Floor J.
    [J]. GYNECOLOGIC ONCOLOGY, 2011, 121 (02) : 269 - 272
  • [2] Response to letter to the editor in response to "Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer"
    O'Malley, David M.
    [J]. GYNECOLOGIC ONCOLOGY, 2012, 124 (01) : 171 - 172
  • [3] Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer
    Hurt, J. D.
    Richardson, D. L.
    Seamon, L. G.
    Fowler, J. F.
    Copeland, L. J.
    Cohn, D. E.
    Eisenhauer, E.
    Salani, R.
    O'Malley, D. M.
    [J]. GYNECOLOGIC ONCOLOGY, 2009, 115 (03) : 396 - 400
  • [4] Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer
    Hurt, J. D.
    Richardson, D. L.
    Seamon, L. G.
    Cohn, D. E.
    Fowler, J. M.
    Copeland, L. J.
    O'Malley, D. M.
    Eisenhauer, E. L.
    Salani, R.
    [J]. GYNECOLOGIC ONCOLOGY, 2009, 112 (02) : S154 - S155
  • [5] Bevacizumab improves progression-free survival in ovarian cancer
    Mayor, Susan
    [J]. BRITISH JOURNAL OF HOSPITAL MEDICINE, 2010, 71 (07) : 371 - 371
  • [6] Adding bevacizumab to chemotherapy improves progression-free survival in ovarian cancer
    Mayor, Susan
    [J]. BRITISH JOURNAL OF HOSPITAL MEDICINE, 2012, 73 (07) : 371 - 371
  • [7] Olaparib plus bevacizumab improves progression-free survival in ovarian cancer
    Gourd, Elizabeth
    [J]. LANCET ONCOLOGY, 2020, 21 (02): : E71 - E71
  • [8] Salvage Therapy of Gemcitabine Plus Endostar Significantly Improves Progression-free Survival (PFS) with Platinum-resistant Recurrent Epithelial Ovarian Cancer
    Su, An
    Zhang, Jing
    Pan, Zhan-He
    Zhou, Qi-Ming
    Lv, Xia
    [J]. ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2013, 14 (03) : 1841 - 1846
  • [9] Niraparib improves progression-free survival in ovarian cancer
    Gourd, Elizabeth
    [J]. LANCET ONCOLOGY, 2019, 20 (11): : E615 - E615
  • [10] The effect of single weekly paclitaxel in heavily pretreated patients with recurrent or persistent advanced ovarian cancer
    Kita, T
    Kikuchi, Y
    Takano, M
    Suzuki, M
    Oowada, M
    Konno, R
    Yamamoto, K
    Inoue, H
    Seto, H
    Yamamoto, T
    Shimizu, K
    [J]. GYNECOLOGIC ONCOLOGY, 2004, 92 (03) : 813 - 818
12345